Division of Cardiology, University of Washington, Seattle, WA, USA.
Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA.
Influenza Other Respir Viruses. 2021 Sep;15(5):569-572. doi: 10.1111/irv.12869. Epub 2021 May 24.
COVID-19 has significant case fatality. Glucocorticoids are the only treatment shown to improve survival, but only among patients requiring supplemental oxygen. WHO advises patients to seek medical care for "trouble breathing," but hypoxemic patients frequently have no respiratory symptoms. Our cohort study of hospitalized COVID-19 patients shows that respiratory symptoms are uncommon and not associated with mortality. By contrast, objective signs of respiratory compromise-oxygen saturation and respiratory rate-are associated with markedly elevated mortality. Our findings support expanding guidelines to include at-home assessment of oxygen saturation and respiratory rate in order to expedite life-saving treatments patients to high-risk COVID-19 patients.
COVID-19 有很高的病死率。糖皮质激素是唯一被证明能提高生存率的治疗方法,但仅对需要补充氧气的患者有效。世界卫生组织建议患者因“呼吸困难”寻求医疗护理,但低氧血症患者通常没有呼吸道症状。我们对住院 COVID-19 患者的队列研究表明,呼吸道症状并不常见,与死亡率无关。相比之下,呼吸功能受损的客观迹象——氧饱和度和呼吸频率——与死亡率显著升高有关。我们的研究结果支持扩大指南,包括在家中评估氧饱和度和呼吸频率,以加快对高危 COVID-19 患者的救生治疗。